Trevena, Inc. (NASDAQ: TRVN) today announced publication of APOLLO-1 (Phase 3) results in The Journal of Pain Research on the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute PainMarch 11, 2019 7:00 AM Pre-Open Stock Movers 03/08: (JYNT) (MDCA) (BIG) Higher; (EB) (FIZZ) (TTOO) Lower (more...)March 8, 2019 9:18 AM After-Hours Movers 03/07: (JYNT) (MDCA) (COST) Higher; (EB) (WTER) (FIZZ) (more...)March 7, 2019 5:42 PM Trevena (TRVN) says FDA informed it that data were not sufficient to support continuation of previously granted Breakthrough Therapy designation for oliceridineMarch 7, 2019 4:32 PM